File Download
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-25444459935
- PMID: 16218174
- WOS: WOS:000232446400008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus
Title | Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus |
---|---|
Authors | |
Issue Date | 2005 |
Citation | Antiviral Therapy, 2005, v. 10, n. 6, p. 745-751 How to Cite? |
Abstract | Kaposi's sarcoma-associated herpesvirus (KSHV) establishes latent infections in lymphocytes and endothelial cells, and latent infection is closely linked to tumorigenesis. As few viral markers are expressed during latency, compounds that can safely and efficiently increase lytic gene expression in vivo have been sought. We have found that the non-tumour-promoting phorbol ester prostratin and the proteasome inhibitor bortezomib induce immediate-early, early and late KSHV gene expression from two lymphoma cell lines in vitro. Their ability to induce lytic gene expression supports a role for phorbol-ester and proteasome-regulated signalling pathways in KSHV reactivation and prompts further investigation of prostratin and bortezomib as therapeutic agents for KSHV-associated malignancies. © 2005 International Medical Press. |
Persistent Identifier | http://hdl.handle.net/10722/285890 |
ISSN | 2023 Impact Factor: 1.3 2023 SCImago Journal Rankings: 0.447 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Brown, Helen J. | - |
dc.contributor.author | McBride, William H. | - |
dc.contributor.author | Zack, Jerome A. | - |
dc.contributor.author | Sun, Ren | - |
dc.date.accessioned | 2020-08-18T04:56:55Z | - |
dc.date.available | 2020-08-18T04:56:55Z | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Antiviral Therapy, 2005, v. 10, n. 6, p. 745-751 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | http://hdl.handle.net/10722/285890 | - |
dc.description.abstract | Kaposi's sarcoma-associated herpesvirus (KSHV) establishes latent infections in lymphocytes and endothelial cells, and latent infection is closely linked to tumorigenesis. As few viral markers are expressed during latency, compounds that can safely and efficiently increase lytic gene expression in vivo have been sought. We have found that the non-tumour-promoting phorbol ester prostratin and the proteasome inhibitor bortezomib induce immediate-early, early and late KSHV gene expression from two lymphoma cell lines in vitro. Their ability to induce lytic gene expression supports a role for phorbol-ester and proteasome-regulated signalling pathways in KSHV reactivation and prompts further investigation of prostratin and bortezomib as therapeutic agents for KSHV-associated malignancies. © 2005 International Medical Press. | - |
dc.language | eng | - |
dc.relation.ispartof | Antiviral Therapy | - |
dc.title | Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.pmid | 16218174 | - |
dc.identifier.scopus | eid_2-s2.0-25444459935 | - |
dc.identifier.volume | 10 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 745 | - |
dc.identifier.epage | 751 | - |
dc.identifier.isi | WOS:000232446400008 | - |
dc.identifier.issnl | 1359-6535 | - |